Company intelligence / Profile preview
Umoja Biopharma
Seattle, Washington, United Statesumoja-biopharma.com ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- Preclinical
01
Overview
Umoja Biopharma has advanced its lead in vivo CAR T cell therapy candidate UB-VV400 targeting CD22 into multiple oncology and autoimmune clinical studies. The company’s approach enables direct generation of CAR T cells within the patient using its proprietary lentiviral vector technology, aiming to improve accessibility, reduce treatment time, and avoid lymphodepleting chemotherapy. Clinical results are pending as programs are early-stage.
- Therapeutic areas
- OncologyImmunology
- Modalities
- In vivo CAR T cell therapy (chimeric antigen receptor T cells generated in the patient)Gene therapy (lentiviral vector delivery)Immunotherapy
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →03
Partnerships
AbbVie – collaboration to leverage VivoVec platform for cancer immunotherapy developmentNona Biosciences – collaboration on advancing in vivo CAR-T therapies
Beyond the preview
Go deeper on Umoja Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Umoja Biopharma.